Cellectis (CLLS) Reports Q2 Loss of EUR0.23/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results
September 8, 2016 5:31 PM EDT- First patient dosed in phase 1 clinical trial for UCART19
- UCART 123 manufacturing ongoing
- Strong cash position of $300 million1 (270 million) as of June 30, 2016
- Revenues and other income of $20 million2 (18 million) in the 2nd quarter of 2016
- Adjusted income attributable to shareholders3 of $9 million2 (8 million) in the 2nd quarter of 2016
NEW YORK--(BUSINESS WIRE)-- Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a... More
